864825-19-4

Usage

Uses

Used in Pharmaceutical Industry:
(S)-Benzyl 1-oxo-1-(2-oxo-2-phenylethylaMino)propan-2-ylcarbaMate is used as an impurity in the production of Eluxadoline (E508195), a medication specifically designed to alleviate the symptoms of irritable bowel syndrome, such as diarrhea and abdominal pain. Its presence in the drug formulation is crucial for understanding the overall safety and efficacy of the medication, as well as for quality control purposes during the manufacturing process.

Upstream product

• 1142-20-7 N-Cbz-Ala 
• 5468-37-1 2-aminoacetophenone hydrochloride 

Downstream Products

• 864825-27-4 (2-(4-hydroxy-2,6-dimethyl-phenyl)-1-{isopropyl-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-carbamoyl}-ethyl)-carbamic acid tert-butyl ester 
• 864825-21-8 benzyl [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 

Relevant academic research and scientific papers

A PROCESS FOR THE PREPARATION OF ELUXADOLINE

The present invention relates to an improved process for the preparation of eluxadoline and its intermediates and that includes the use of an aqueous surfactant solution in the preparation of N2-[(benzyloxy)carbonyl]-N-(2-oxo-2-phenylethyl)-L-a

Identification of a dual δ or antagonist/μ or agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)

A small set of acyclic analogs 5 were prepared to explore their structure-activity relationships (SARs) relative to heterocyclic core, opioid receptor (OR) agonists 4. Compound 5l was found to have very favorable OR binding affinities at the δ and μ ORs (r Ki δ = 1.3 nM; r Ki μ = 0.9 nM; h Ki μ = 1.7 nM), with less affinity for the κ OR (gp Ki κ = 55 nM). The OR functional profile for 5l varied from the previously described dual δ/μ OR agonists 4, with 5l being a potent, mixed dual δ OR antagonist/μ OR agonist [δ IC50 = 89 nM (HVD); μ EC50 = 1 nM (GPI); κ EC50 = 1.6 μM (GPC)]. Compound 5l has progressed through a clinical Phase II Proof of Concept study on 800 patients suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-d). This Phase II study was recently completed successfully, with 5l demonstrating statistically significant efficacy over placebo.

PROCESS FOR THE PREPARATION OF OPIOID MODULATORS

The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestina

NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS

The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may